Full Breakdown
FDA Removes Barriers to Real-World Evidence in Drug and Device Approvals
12/16/2025, 4:03:54 AM
Key Policy Change in FDA Guidance
On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant shift in its approach to the use of real-world evidence (RWE) in drug and medical device applications. The agency will now accept RWE without the requirement for identifiable individual patient data, a move aimed at streamlining the approval process for new treatments. This policy change is expected to facilitate the use of large, de-identified datasets, such as those from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, hospital systems, and insurance claims databases.
Historically, the FDA's stringent requirements for RWE submission limited its use in applications, with only 35 drugs, biologics, or vaccines incorporating RWE since 2016. In contrast, over 250 medical devices have included RWE in their premarket authorizations during the same period, although the rate of such authorizations has plateaued.
Implications for Drug and Device Approvals
FDA Commissioner Marty Makary emphasized that this reform will eliminate unnecessary barriers and expedite access to life-changing treatments. He stated, "We're removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster." The FDA will now evaluate RWE on a case-by-case basis, allowing for broader insights into treatment efficacy outside traditional clinical trial settings.
The agency's new guidance aligns with previous calls from President Donald Trump to accelerate medical innovation and reduce regulatory red tape. Makary noted that the previous requirements were so burdensome that only 12 drugs had successfully included RWE in their applications over the past 14 years. By lifting these restrictions, the FDA aims to cut costs, reduce delays, and ultimately lower drug prices.
Criticism and Opposition
Despite the positive reception from some stakeholders, there are concerns regarding the adequacy of RWE in ensuring patient safety and treatment efficacy. Critics argue that while RWE can provide valuable insights, it may not always meet the rigorous standards of controlled clinical trials. The FDA maintains that it will still require clinical trials for most drugs, with exceptions for rare diseases.
Official Statements & Responses
In an interview, Makary stated, "One thing we've got to do is deliver on President Trump's goal to give more cures and meaningful treatments to Americans, cutting the red tape, streamlining the FDA." He further clarified that while the agency is encouraging the use of broader datasets, it will still inform companies if the submitted RWE does not meet their standards.
Verbatim Quotes
- “We're removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster,” — Marty Makary, FDA Commissioner
- “Right now, they say that they've been admitting real-world data into applications, but the requirements have been so onerous that only 12 drugs in the last 14 years have had real-world data in their approval application because the requirements just got so bureaucratic,” — Marty Makary, FDA Commissioner
- “That's going to allow for more innovation and less delays and lower R&D costs, which could translate to lower drug prices,” — Marty Makary, FDA Commissioner
What's Next
The FDA plans to continue refining its guidance on RWE for drugs and biologics, potentially leading to a broader acceptance of real-world data in regulatory submissions. This ongoing evolution in policy may significantly impact the landscape of drug and device approvals in the coming years.
